Your session is about to expire
← Back to Search
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
BMI ≥27 kg/m² and <30 kg/m² with at least one of the following weight-related comorbidities: hypertension on blood pressure (BP)-lowering medication, dyslipidemia on lipid-lowering medication, cardiovascular (CV) disease (e.g., ischemic CV disease, New York Heart Association (NYHA) Functional Classification Class 1 or II Heart Failure), obstructive sleep apnea
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, week 48
Awards & highlights
Study Summary
This trial aims to study the effectiveness and safety of LY3841136 for managing weight in adults who are overweight or have obesity. The study will last for about 64 weeks and participants may need to
Who is the study for?
This trial is for adults who are overweight or have obesity. Specific details about eligibility criteria were not provided, so interested individuals should consult the study team for more information.Check my eligibility
What is being tested?
The study is testing a new medication called LY3841136 against a placebo to see if it helps with weight management in obese or overweight adults. The trial will go on for about 64 weeks and may require participants to attend up to 13 visits.See study design
What are the potential side effects?
Potential side effects of LY3841136 are not listed here, but typically, weight management drugs can cause gastrointestinal issues, headaches, increased heart rate, and other symptoms. Participants should ask the research team for detailed side effect information.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
My BMI is between 27 and 30, and I have a weight-related health issue.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ baseline, week 48
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, week 48
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Percent Change from Baseline in Body Weight
Secondary outcome measures
Change from Baseline in Body Mass Index (BMI)
Change from Baseline in Body Weight
PK: Maximum Concentration (Cmax) of LY3841136
+3 moreTrial Design
6Treatment groups
Experimental Treatment
Placebo Group
Group I: LY3841136 Dose 5Experimental Treatment1 Intervention
Participants will receive LY3841136 SC.
Group II: LY3841136 Dose 4Experimental Treatment1 Intervention
Participants will receive LY3841136 SC.
Group III: LY3841136 Dose 3Experimental Treatment1 Intervention
Participants will receive LY3841136 SC.
Group IV: LY3841136 Dose 2Experimental Treatment1 Intervention
Participants will receive LY3841136 SC.
Group V: LY3841136 Dose 1Experimental Treatment1 Intervention
Participants will receive LY3841136 subcutaneously (SC).
Group VI: PlaceboPlacebo Group1 Intervention
Participants will receive LY3841136 matching placebo.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
LY3841136
2022
Completed Phase 1
~150
Find a Location
Who is running the clinical trial?
Eli Lilly and CompanyLead Sponsor
2,620 Previous Clinical Trials
3,216,374 Total Patients Enrolled
55 Trials studying Obesity
50,994 Patients Enrolled for Obesity
Study DirectorEli Lilly and Company
1,348 Previous Clinical Trials
415,520 Total Patients Enrolled
38 Trials studying Obesity
30,713 Patients Enrolled for Obesity
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Is it possible for me to enroll as a participant in this medical study?
"To be eligible for participation in this trial, individuals must have a diagnosis of obesity and fall within the age range of 18 to 75 years. The study aims to recruit a total of 225 participants."
Answered by AI
Is the current clinical trial open for patient enrollment at this time?
"Based on the information provided by clinicaltrials.gov, this particular clinical trial is not currently accepting new participants. The study was originally posted on February 16th, 2024 and last revised on January 21st, 2024. However, it's worth noting that there are currently 1153 other ongoing trials actively seeking eligible patients at this time."
Answered by AI
Is the age criterion for this research study limited to individuals below 80 years?
"Individuals aged 18 and above but below the age of 75 are eligible for enrollment in this clinical trial."
Answered by AI
What are the potential risks associated with administering Dose 2 of LY3841136 to patients?
"Based on our assessment, the safety of LY3841136 Dose 2 is rated as a 2 because this trial is in Phase 2, indicating that there is existing data supporting its safety but none yet supporting efficacy."
Answered by AI
Who else is applying?
What site did they apply to?
Peninsula Research Associates
Las Vegas Medical Research
The Institute for Liver Health dba Arizona Clinical Trials
Other
What portion of applicants met pre-screening criteria?
Did not meet criteria
Met criteria
Why did patients apply to this trial?
To become healthier. I want to lose weight. Need help to lose weight. I am obese and do not wish to be.
PatientReceived 2+ prior treatments
I’ve been on a diet my whole life.
PatientReceived 2+ prior treatments
What questions have other patients asked about this trial?
How many visits will this study entail?
PatientReceived 1 prior treatment
Recent research and studies
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger